ArticleClinical rheumatology2018
Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus.
Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Prevalence and incidence of interstitial lung diseases in systemic lupus erythematosus: systematic review and meta-analyses.Lupus science & medicine · 2026Pooled it
- Article
- Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies.Journal of translational autoimmunity · 2022Article
- Untangling COVID-19 and autoimmunity: Identification of plausible targets suggests multi organ involvement.Molecular immunology · 2021Article
- Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The purpose of this study is to investigate the clinical and serological associations of anti-ribosomal P0 protein antibodies (anti-Rib-P0) in patients with systemic lupus erythematosus (SLE). The sera of 470 patients with SLE and 124 patients with primary Sjogren's Syndrome (pSS) were collected. Line immunoassay (LIA) was used to detect anti-Rib-P0 and other related antibodies. A complete laboratory evaluation and clinical examination were also performed in each SLE patient. The prevalence of anti-Rib-P0 in SLE patients was significantly higher than that in pSS patients (35.74 vs 6.45%) (P < 0.001). There was a significantly lower prevalence of cardiac involvement in anti-Rib-P0-positive SLE patients compared to anti-Rib-P0-negative SLE patients (P = 0.019); no significant associations of anti-Rib-P0 antibodies with encephalopathy manifestations and other vital organs involvement were observed. Anti-nucleosomes, anti-dsDNA, anti-Histones, anti-SmD1, and anti-U1snRNP were significantly associated with serum anti-Rib-P0 antibodies positivity in SLE patients (all P < 0.05). The sensitivity and specificity of the anti-Rib-P0 antibodies to diagnose SLE were 35.74 and 93.55%, respectively. There is a higher prevalence of anti-Rib-P0 in SLE patients. Anti-Rib-P0 positivity may indicate lower cardiac involvement for SLE patients. It may serve as an important complementary parameter in SLE, in addition to anti-dsDNA, anti-SmD1, and anti-nucleosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.